Three Apple Daily executives released on bail

Three of the five Apple Daily executives, arrested by national security police on Thursday, were released on bail on Friday evening. Their release came hours after police charged the other two - editor-in-chief, Ryan Law, and chief executive, Cheung Kim-hung - with collusion with foreign or external forces. On leaving...

Linkhum Announces the Launching of Its Newest Financial Platform

SEAPRWire / June 18, 2021 -- Recently, Linkhum Investment Limited has announced the launching of its newest financial platform (https://linkhuminvestment.com), providing clients with a wide range of financial products, including currency pairs, metal encrypted digital currencies, energy, indices, and stocks. The company's official website has been localized into 15 languages, and the...

Ex-museum staff jailed six months for ‘tip-off’ photo

A former history museum worker has been jailed for six months for posting a photo of police officers online during the siege of the Polytechnic University in November 2019. Kowloon City Court on Friday convicted Chan Chi-wah, 44, of obstructing police. To go with the picture taken from the museum,...

Betty Fung to head West Kowloon cultural hub

West Kowloon Cultural District Authority (WKCDA) on Friday appointed former government official Betty Fung as its CEO for the next three years. Fung, who has been the authority's acting CEO after it parted ways with former chief Duncan Pescod last year, will officially take the helm in October. During a...

‘Make Covid info accessible for mentally disabled’

A social work scholar says people with intellectual disabilities are being left behind because they struggle to follow information put out by the Hong Kong government about Covid-19. Angela Cui, an assistant professor at the Chinese University, took part in a global study on the impact of the pandemic on...

Malaysia Permission Granted for COVID-19 Test Kit from China for Emergency Use; Homegrown Holista Colltech Receives Initial Order for 15,000 Units for Deployment

KUALA LUMPUR, Jun 18, 2021 - (ACN Newswire via SEAPRWire.com) - Amid rising concerns about the threat and economic impact of COVID-19, Holista Colltech Limited has been granted permission for Special access under the Medical Device (Exemption) Order 2016, from the Medical Devices Authority ("MDA") of Malaysia's Ministry of Health...

馬來西亞允許了來自中國的新冠肺炎測試劑盒以供為緊急使用;Holista Colltech 收到 15,000 單位的初始訂單

KUALA LUMPUR, Jun 18, 2021 - (亞太商訊 via SEAPRWire.com) - 由於新冠肺炎帶來的威脅和經濟影響的擔憂日益加劇, Holista Colltech Limited 已根據2016 年醫療器械(豁免)令獲得馬來西亞衛生部(“MOH”)醫療器械管理局(“MDA”)的特殊許可,可進口和分銷由中國廣東和信科技股份有限公司(“和信”)開發和製造的抗原快速檢測試劑盒(RTK-AG)。獲得該批准後,公司已在馬來西亞獲得了 15,000 台的初始訂單。Holista Colltech Limited(“Holista”)是一家總部位於八打靈再也並在澳大利亞證券交易所(“ASX”HCT”)上市的天然保健和保健產品專家,表示HecinTM 2019-nCOV 診斷測試劑盒將用於鼻拭子中檢測SARS-CoV-2 病毒抗原, 並在15分鐘內得到結果。抗原測試病毒的塗層或蛋白質,而聚合酶鏈反應 (“PCR”) 測試其核酸或遺傳物質(也稱為 RNA)。前者可以在幾分鐘內交付結果並且成本較低;後者雖然更準確,但可能需要幾天時間,而且成本更高。這 15,000 個單位將於 6 月底運往 Mutiara診所,這是 Amegajaya Sdn Bhd 的一部分,Amegajaya Sdn Bhd 是一家與衛生部和相關組織密切合作的醫療諮詢公司。 Holista 全資擁有的 Holista Biotech Sdn. Bhd. 獲得的初始訂單 價值約 95,000 澳元(73,000 美元)。這些試劑盒將由...

科濟藥業正式登陸港交所 產品管線多元化成長潛力巨大

HONG KONG, Jun 18, 2021 - (亞太商訊 via SEAPRWire.com) - 今日,科濟藥業(2171.HK)正式在港交所掛牌上市,發售價為32.80港元/股。招股書資料顯示,公司發行的股份總數約為9474.7萬股,其中香港發售約947.5萬股,國際發售8527.2萬股。高盛(亞洲)有限責任公司和UBS Securities Hong Kong Limited為聯席保薦人。科濟藥業此次IPO共引入9名基石投資者,包括LAV、新華資本、CloudAlpha、睿遠、WT、廣發基金、Dymon Asia、常春藤、南方基金。基石投資者認購合共47,322,000股發售股份,佔全球發售項下發售股份數目的約49.95%。據悉,科濟藥業成立於2014年,是一家在中國及美國營運的臨床階段的生物製藥公司,專注於治療實體瘤和血液惡性腫瘤的創新細胞療法。公司的聯合創始人、首席執行官和首席科學官李宗海博士是CAR-T細胞療法領域的領軍人物之一,曾在多個著名科學期刊上發表了100多篇同行評審的科學論文。李博士同時為擁有200多項專利或專利申請的發明家,在生物製藥領域擁有豐富的經驗。在研管線多元化 核心產品有望占得先機研發方面,目前科濟藥業已建立11款候選產品的差異化管線,其中6個正處於臨床階段。在11個候選產品中,10個是CAR-T細胞療法,其中5個處於臨床階段。公司的願景是成為能為全球癌症患者帶來創新和差異化的細胞療法並使癌症可治癒的全球生物製藥的領導者。截至2021年2月18日,科濟藥業已在中國、美國和加拿大獲得7個CAR-T療法的IND許可,這在中國所有CAR-T公司中排名第一。公司的核心候選產品——CT053,主要用於治療復發/難治多發性骨髓瘤(一種血液惡性腫瘤),在公司管線產品中,CT053處於最成熟階段。CT053已於2019年獲得美國FDA的RMAT和孤兒藥認定,並分別於2019年和2020年獲得EMA的PRIME和孤兒藥產品認定,2020年獲得國家藥監局的突破性治療藥物品種認定。當前,公司完成了I期研究,並正在中國進行CT053治療R/R MM的I/II期臨床試驗的關鍵II期研究,在北美正在完成Ib期臨床試驗並就啟動關鍵II期臨床試驗與美國FDA溝通。相當於這款原研藥得到了世界主要經濟體美國、歐洲和中國的認可,公司有望在此領域搶得先機。同時,另一款候選產品CT041,是一種全球潛在同類首創的、靶向CLDN18.2自體CAR-T候選產品,開發用於治療CLDN18.2陽性實體瘤,主要治療胃癌╱胃食管結合部癌及胰腺癌。根據弗若斯特沙利文的資料,CT041為全球唯一獲得IND許可的靶向CLDN18.2的CART-T候選產品。目前,該產品已獲得IND批准,正在進行臨床試驗研究,CT041在臨床試驗中表現出良好的治療效果及安全性。科濟藥業作為目前全球唯一的獲得IND許可的靶向CLDN18.2的CART-T候選產品研究企業,公司有望在胃癌和胰腺癌巨大市場中率先搶佔制高點。股東背景實力強大 市場前景廣闊招股書資料顯示,科濟藥業此前進行六輪融資,主要投資者包括高瓴資本、天士力、佐力藥業等業內知名投資者。公司此次IPO募資所得,將主要用於:約30%用於進一步開發公司的核心候選產品;約31%為持續及規劃研發公司的其他管線候選產品提供資金;約20%開發全面的製造及商業化能力;約10%升級公司的嵌合抗原受體T細胞(CAR-T)技術及為早期研發提供資金;約9%用作營運資金及其他一般公司用途。從市場潛力方面來看,根據弗若斯特沙利文的資料,預計全球CAR-T細胞療法市場將從2019年7億美元增至2024年66億美元,2019年至2024年的複合年增長率為55%。預期截至2030年,全球CAR-T市場預計達至218億美元,2024年至2030年的複合增長率為22.1%。未來,隨著全球癌症患病率持續上升、適應症向實體瘤擴展、產品認可度的提升及政策利好等因素驅動,科濟藥業作為該領域的領導者,憑藉豐富的在研管線、強大的研發能力以及產品的先發優勢,成長空間巨大。於港交所上市後,科濟藥業有望進一步強化行業地位,快速搶佔市場份額,公司的未來值得期待。 Copyright 2021 亞太商訊. All rights reserved. (via SEAPRWire)

Hong Kong’s jobless rate falls to lowest in a year

Hong Kong's unemployment rate has dropped to its lowest level in a year, falling to six percent in the three months to the end of May, down from 6.4 percent. Government figures show the SAR's jobless rate has fallen gradually since reaching a 16-year peak of 7.2 percent for the...

John Lee’s comments ‘ominous’: journalism lecturer

Comments by Hong Kong’s security chief about national security-related arrests at the Apple Daily are “ominous”, a University of Hong Kong journalism lecturer said on Thursday, warning they could pave the way for tighter government regulation of the media industry. Senior lecturer Sharron Fast was responding to comments by Security...

Cash handouts from July for those in housing queue

The government will from next month start giving out up to HK$3,900 a month to families who have been on the waiting list for a public housing flat for more than three years. The scheme was announced by Chief Executive Carrie Lam in her latest policy address, and officials revealed...

‘Public want more info on vaccine compensation cases’

A patients' rights activist on Thursday urged the government to release more details about cases where people receive compensation after suffering complications from Covid-19 jabs. A HK$1 billion fund set up for the purpose has so far received 74 applications. A total of HK$450,000 has been granted to date, for...

This is the worst era of Hong Kong: Apple Daily

Apple Daily on Thursday vowed to fight on despite another police raid and the arrest of several senior executives, saying staff will "loyally defend their posts". In a letter to readers, the newspaper said every one of its journalists has reported the truth, legally and reasonably. "Everyone at Apple Daily...